RUNX1T1 and acute myeloid leukemia: In a prospective multicenter trial, Jourdan et al.16 demonstrated, by RQ-PCR, that a less than 3-log MRD reduction of RUNX1-RUNX1T1 transcript after the first consolidation was associated with a higher specific hazard of relapse in young CBF-AML patients.